JP Morgan Chase
ADPT icon

JP Morgan Chase’s Adaptive Biotechnologies ADPT Stock Holding History

JP Morgan Chase’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.33M Sell
259,176
-6,575
-2% -$105K ﹤0.01% 3689
2025
Q4 		$4.32M Buy
265,751
+30,083
+13% +$491K ﹤0.01% 3448
2025
Q3 		$3.53M Sell
235,668
-799,246
-77% -$9.74M ﹤0.01% 3649
2025
Q2 		$12.1M Sell
1,034,914
-49,269
-5% -$448K ﹤0.01% 2392
2025
Q1 		$8.06M Buy
1,084,183
+424,977
+64% +$3.27M ﹤0.01% 2744
2024
Q4 		$3.95M Sell
659,206
-228,627
-26% -$1.26M ﹤0.01% 3577
2024
Q3 		$4.55M Sell
887,833
-14,724
-2% -$64.2K ﹤0.01% 3287
2024
Q2 		$3.27M Buy
902,557
+689,050
+323% +$2.19M ﹤0.01% 3376
2024
Q1 		$685K Sell
213,507
-68,461
-24% -$265K ﹤0.01% 4600
2023
Q4 		$1.38M Sell
281,968
-20,156
-7% -$92K ﹤0.01% 4114
2023
Q3 		$1.65M Sell
302,124
-9,072
-3% -$60K ﹤0.01% 3697
2023
Q2 		$2.09M Sell
311,196
-212,552
-41% -$1.58M ﹤0.01% 3511
2023
Q1 		$4.63M Buy
523,748
+120,353
+30% +$1.06M ﹤0.01% 2882
2022
Q4 		$3.08M Sell
403,395
-140,849
-26% -$1.1M ﹤0.01% 3221
2022
Q3 		$3.88M Sell
544,244
-16,544
-3% -$156K ﹤0.01% 2955
2022
Q2 		$4.54M Buy
560,788
+231,673
+70% +$2.04M ﹤0.01% 2860
2022
Q1 		$4.57M Buy
329,115
+49,451
+18% +$777K ﹤0.01% 3080
2021
Q4 		$7.85M Buy
279,664
+96,280
+53% +$2.95M ﹤0.01% 2664
2021
Q3 		$6.23M Sell
183,384
-13,959
-7% -$505K ﹤0.01% 2849
2021
Q2 		$8.06M Sell
197,343
-1,191,290
-86% -$46.3M ﹤0.01% 2619
2021
Q1 		$55.9M Buy
1,388,633
+62,566
+5% +$3.39M 0.01% 1112
2020
Q4 		$78.4M Sell
1,326,067
-91,224
-6% -$4.7M 0.01% 876
2020
Q3 		$68.1M Buy
1,417,291
+538,418
+61% +$22.6M 0.01% 840
2020
Q2 		$42.5M Buy
878,873
+203,753
+30% +$7.43M 0.01% 968
2020
Q1 		$18.8M Buy
675,120
+215,680
+47% +$6.02M ﹤0.01% 1297
2019
Q4 		$13.7M Sell
459,440
-411,284
-47% -$11.8M ﹤0.01% 1858
2019
Q3 		$26.9M Buy
870,724
+490,496
+129% +$20M 0.01% 1371
2019
Q2 		$15.3M Buy
+380,228
New +$16.8M ﹤0.01% 1763

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase's ADPT Position: Q1 2026 in Review

JP Morgan Chase reduced its Adaptive Biotechnologies (ADPT) stake by 2.5% in Q1 2026, selling an estimated $105K and leaving 259,176 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3689.

JP Morgan Chase first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $78.4M in Q4 2020. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • JP Morgan Chase held 259,176 shares of Adaptive Biotechnologies worth $3.33M as of Q1 2026.
  • JP Morgan Chase sold 6,575 Adaptive Biotechnologies shares in Q1 2026, an estimated $105K.
  • Adaptive Biotechnologies made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3689 holding.
  • JP Morgan Chase first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's Adaptive Biotechnologies position peaked at $78.4M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.